Compare IQV & HIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | HIG |
|---|---|---|
| Founded | 1982 | 1810 |
| Country | United States | United States |
| Employees | 93000 | 19200 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 37.3B |
| IPO Year | 2013 | N/A |
| Metric | IQV | HIG |
|---|---|---|
| Price | $172.70 | $138.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 17 |
| Target Price | ★ $230.56 | $148.38 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 7.84 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.77 | $6.06 |
| Revenue Next Year | $5.87 | $4.13 |
| P/E Ratio | $21.79 | ★ $10.61 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $134.65 | $112.81 |
| 52 Week High | $247.05 | $143.98 |
| Indicator | IQV | HIG |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 58.12 |
| Support Level | $159.42 | $129.04 |
| Resistance Level | $193.26 | $139.25 |
| Average True Range (ATR) | 6.17 | 2.20 |
| MACD | 1.66 | 0.56 |
| Stochastic Oscillator | 63.81 | 99.51 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments, including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.